SF3B1-mutated and SF3B1-unmutated PMF suggests that the former is not a distinct clinicopathological entity but the result of a secondary mutation that promotes the formation of RS. Accordingly, it is possible that the percentage of bone marrow RS reflects the clone size that is affected by SF3B1 mutation. This particular observation is consistent with the aforementioned close association between MDS-RS and SF3B1 mutations, and is strongly suggestive of a causal relationship between SF3B1 mutations and the RS phenotype. RS are also found in hereditary sideroblastic anemias, including those with germline ABCB7 (ATP-binding cassette, sub-family B, member 7) mutations. ABCB7 is a mitochondrial iron transporter molecule and the downregulation of ABCB7 has been reported in RARS.
Myelodysplastic syndromes (MDS) are neoplastic diseases of the hematopoietic stem cell with a pronounced heterogeneity regarding morphology and clinical course. 1 In order to understand the complex pathophysiology, many efforts have been made to unravel the molecular background of MDS. Mutations in several genes were identified in the last few years, including TET2, Some of these molecular aberrations provide prognostic information that allows further sub-classification and possibly risk-directed therapeutic intervention. 8, 9 Recent studies using next-generation sequencing approaches identified previously unknown aberrations of the Splicing factor 3b, subunit 1 (SF3B1) in about 20% of MDS patients. 10 --12 The prevalence of SF3B1 mutations was up to 75% in the subgroup of MDS defined by the presence of ring sideroblasts (RS). 10 SF3B1 is located at chromosomal band 2q33 and encodes a core component of the U2 small nuclear ribonucleoprotein complex (U2 snRNP). U2 snRNP is a part of the catalytic site of the spliceosome that processes pre-messenger RNA to mature mRNA and thus regulates the diversity of splice variants. 13 To date, little is known about the clinical phenotype and prognostic implications of SF3B1 mutations in MDS. To address this question, the current study used direct sequencing to analyze the mutational hotspots of SF3B1 (exons 13 --16) in a large series of 317 MDS patients comprising all subtypes of the WHO 2008 classification. Informed consent was obtained from all patients in accordance with the Declaration of Helsinki. This study was approved by the institutional review board of Hannover Medical School and the Paris Centre ethics committee. Cell samples were collected at the time of enrolment in multicenter clinical trials conducted either in Germany (n ¼ 193) or France (n ¼ 124). Treatment details for both cohorts have been published earlier. 9, 14, 15 The statistical analyses were performed with the statistical software package SPSS 19.0 (SPSS Science, Chicago, IL, USA). Overall-survival and acute myeloid leukemia (AML) progression rates were similar with 5-year overall survival (OS) of 36% in the German vs 34% in the French cohort (P ¼ 0.45) and AML progression rates of 27.5% vs 21% (P ¼ 0.22), respectively.
Heterozygous point mutations were detected in 47 out of the 317 patients (14.8%). Among the 47 patients, 30 harbored a K700E, 6 cases a K666N, 2 patients either a H662Y or a D781G substitution while only single cases showed a K666Q, R625L, R625C, R625H, R625G, E622D or H662Q substitution. The somatic nature of these mutations was confirmed by sequencing non-tumoral CD3 þ cells in six patients (4 Â K700E, 1 Â D781G, 1 Â R625L). Sixty percent of patients with mutations in the SF3B1 gene had at least 15% of RS in their bone marrow (60% vs 8% in patients without RS, Po0.001). The prevalence of SF3B1 mutations in all patients with RS (RARS or RCMD-RS) was 56% (28 out of 50) in our study. Patients with SF3B1 mutations were older than wildtype patients (P ¼ 0.028) and had significantly less bone marrow blasts (P ¼ 0.003), however, no differences were observed for baseline characteristics such as gender, cytogenetic risk group, International Prognostic Scoring System (IPSS) score or ferritin levels (Table 1) . SF3B1 mutated compared with SF3B1 wildtype patients presented with a distinct hemogram at diagnosis. While median hemoglobin levels were significantly lower (8.4 vs 9.8 g dl À1 ; patients studied, n ¼ 281; P ¼ 0.02) in SF3B1 mutated patients, they showed higher median white cell count (6.1 Â 10 9 vs 4.4 Â 10 9 per liter; patients studied, n ¼ 123; P ¼ 0.01), higher median peripheral-neutrophil count (3.1 Â 10 9 vs 2.2 Â 10 9 per liter; patients studied, n ¼ 122; P ¼ 0.03) and a higher median platelet count (276 Â 10 9 vs 145 Â 10 9 per liter, patients studied, n ¼ 124;
Po0.001). Morphologic analysis performed at diagnosis revealed that in SF3B1 mutated patients, dysplastic features affected more often the erythroid lineage (79% vs 46% in SF3B1 wildtype patients; patients studied, n ¼ 108; P ¼ 0.03), whereas the megakaryocytic lineage was less often dysplastic (29% vs 62%, patients studied, n ¼ 105; P ¼ 0.021). The frequency of dysplastic myeloid cells was similar between SF3B1 mutated and SF3B1 wildtype patients (43% vs 64%; patients studied, n ¼ 109; P ¼ 0.142). Concomitant mutations of other known MDS targets included ASXL1 in five SF3B1 mutated patients (only analyzed in the German cohort), TET2 in three cases, JAK2 V617F in two patients (TET2 and JAK2 V617F only analyzed in the French cohort), and IDH1/2 and DNMT3A in two patients. Patient characteristics are shown in Table 1 .
Data on clinical outcome were available for 253 patients, of whom 37 (14.6%) were positive for SF3B1 mutations and thus constitute to date the largest MDS cohort to assess the prognostic impact of SF3B1 mutations. OS endpoints, measured from the date of first sample collection, were death (failure) and alive at last follow-up (censored). Time to AML progression was measured from date of first sample collection to the time of AML diagnosis. AML was defined according to the 2008 WHO classification. The median follow-up time for patients alive was 2.9 years (range: 0.2 --11.75 years). Univariate analysis revealed no influence of the SF3B1 mutation status on OS or time to AML progression (OS: P ¼ 0.64; time to AML progression: P ¼ 0.36; Figures 1a and b) . This was also true upon evaluation of the different IPSS and cytogenetic risk groups (Figures 1c --f) , the German or the French cohort separately or limiting the analysis to patients with or without RS (Figures 1g and h, data not shown) . No difference for OS and time to AML progression was observed when distinguishing SF3B1 mutated patients according to their mutation localization (K700E vs mutations at other loci, data not shown).
These results are in contrast to a recently described study indicating that SF3B1 mutations define a benign clinical phenotype. 12 Several explanations might contribute to this observation. First, the two studied populations might be heterogeneous. In the report from Papaemmanuil et al. 12 on 123 MDS patients with follow-up data, the prevalence of SF3B1 mutations was almost twice as high as in our cohort (34/ 123 ¼ 27.6% compared with 37/253 ¼ 14.6%). Unfortunately, little is reported on the distribution of WHO subtypes, treatment regimens, IPSS and cytogenetic risk-groups, making a comparison more difficult. Our presented analysis represents a cohort that is certainly shifted to low-risk MDS patients as 73% of analyzed patients were either classified into IPSS low or intermediate-1 risk groups. Nevertheless, when restricting the outcome analyses to these patients, no impact on OS or time to AML progression was observed (Figures 1c --f) . Second, our cohort comprises patients from different multicenter treatment trials that investigated the use of all-trans retinoic acid (ATRA), antithymocyte globulin, deferasirox, lenalidomide or decitabine for treatment of MDS, which might have influenced the prognostic value of SF3B1 mutations in our cohort.
In summary, we report SF3B1 mutations with a prevalence of 14.8% as a recurrent molecular aberration in MDS. SF3B1 mutated patients presented with a distinct clinical and morphological phenotype associated with the presence of RS and more pronounced defects in the erythroid lineage. The association of a specific gene mutation with a distinct morphology such as RS, suggests that SF3B1 has a unique role in the pathogenesis of MDS. In this large series of MDS patients, the SF3B1 mutation status was not associated with time to AML progression or OS regardless if all patients or only the subgroup of patients with RS were included in the analyses. Additional studies might resolve this discrepancy to earlier reports. Furthermore, functional analyses are warranted to unravel the mechanisms of SF3B1 in MDS disease genesis and evolution. 24 (52) 14 (5) 
4 (9) 10 (4 Abbreviations: del(5q), MDS with isolated del(5q); IPSS, International Prognostic Scoring System; MDS-U, MDS-unclassifiable;RA, refractory anemia; RAEB-1, refractory anemia with excess blasts-1; RAEB-2, refractory anemia with excess blasts-2; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RS, ring sideroblasts. The introduction of imatinib just over ten years ago revolutionized chronic myeloid leukemia (CML) therapy, making long-term survival a reality for the majority of newly diagnosed patients. Unfortunately, residual disease remains detectable in most patients, and even patients with undetectable BCR --ABL (complete molecular response) have a substantial risk of disease recurrence upon discontinuation of imatinib. 1 Studies to understand the mechanism(s) underlying CML persistence in spite of ongoing, successful TKI-based disease management have mainly focused on cellintrinsic mechanisms. However, there is compelling evidence that the microenvironment has an important role in resistance to chemotherapy by providing critical survival cues to cells. 2 Therefore, we hypothesized that extrinsic factors may also contribute to CML disease persistence despite effective inhibition of BCR --ABL kinase activity by imatinib and second generation ABL inhibitors.
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To investigate these extrinsic survival factors in a more physiologic context, we used immortalized human bone marrow stromal cells as a model of the microenvironment. 3 We found that conditioned media (CM) from HS-5, but not HS-23 or HS-27a, enhanced survival of CML cell lines in the presence of imatinib, dasatinib and nilotinib (Supplementary Figure 1) , consistent with previous reports. 4 ,5 Furthermore, we found that CML CD34 þ cells co-cultured with HS-5 cells, or cultured in transwells over HS-5 cells, also attenuated the effects of imatinib on colony formation (Supplementary Figure 1) . These data suggested that soluble factors may be responsible for HS-5-mediated protection from TKIs. We quantified the relative abundance of several cytokines in CM from the three human stromal cell lines to identify putative protective factors and found high concentrations of interleukin-6 (IL-6), interleukin-8 (IL-8), growth-related oncogene 1 (GRO1),
